Literature DB >> 1526010

Sensitive and selective liquid-chromatographic assay of fluoxetine and norfluoxetine in plasma with fluorescence detection after precolumn derivatization.

R F Suckow1, M F Zhang, T B Cooper.   

Abstract

We determined fluoxetine (Prozac) and its major metabolite norfluoxetine in plasma by liquid chromatography with fluorescence detection. After liquid-liquid extraction from 1 mL of plasma, the extract was derivatized at room temperature with dansyl chloride, and the highly fluorescent derivatives were chromatographed with a reversed-phase C18 column and a mobile phase of phosphate buffer and acetonitrile. Dansylated fluoxetine, norfluoxetine, and the internal standard were eluted in less than 14 min with no interference from endogenous material. The calibration curve was linear over the concentration range 25-800 micrograms/L with inter- and intra-assay imprecision (CV) of less than 10%. Validity of the assay was checked by comparing results for 110 patients' samples with those by a liquid-chromatographic method with ultraviolet detection (r = 0.993 for fluoxetine, 0.957 for norfluoxetine). The identity of the dansylated derivatives was verified by positive chemical ionization mass spectroscopy. The lower limit of detection was approximately 3 micrograms/L. Because no major antidepressant, neuroleptic, or respective drug metabolites interfere with the quantification of fluoxetine and norfluoxetine, this is a useful procedure for pharmacokinetic studies and in clinical settings.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526010

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

2.  Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice.

Authors:  Iva Dincheva; Jianmin Yang; Anfei Li; Tina Marinic; Helena Freilingsdorf; Chienchun Huang; B J Casey; Barbara Hempstead; Charles E Glatt; Francis S Lee; Kevin G Bath; Deqiang Jing
Journal:  Am J Psychiatry       Date:  2017-10-31       Impact factor: 18.112

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).

Authors:  Rivka L Shoulson; Raymond L Stark; Marianne Garland
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-11       Impact factor: 1.232

Review 5.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

6.  Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice.

Authors:  Georgia E Hodes; Tiffany E Hill-Smith; Raymond F Suckow; Thomas B Cooper; Irwin Lucki
Journal:  J Pharmacol Exp Ther       Date:  2009-10-14       Impact factor: 4.030

7.  Impact of social status and antidepressant treatment on neurogenesis in the baboon hippocampus.

Authors:  Melody V Wu; Jul Lea Shamy; Gillinder Bedi; Chien-Wen J Choi; Melanie M Wall; Victoria Arango; Maura Boldrini; Richard W Foltin; René Hen
Journal:  Neuropsychopharmacology       Date:  2014-02-12       Impact factor: 7.853

8.  Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.

Authors:  Helen B Simpson; Edna B Foa; Michael G Wheaton; Thea Gallagher; Marina Gershkovich; Andrew B Schmidt; Jonathan D Huppert; Raphael B Campeas; Patricia A Imms; Shawn P Cahill; Christina DiChiara; Steven D Tsao; Anthony C Puliafico; Daniel Chazin; Anu Asnaani; Kelly Moore; Jeremy Tyler; Shari A Steinman; Arturo Sanchez-LaCay; Sandy Capaldi; Ivar Snorrason; Elizabeth Turk-Karan; Donna Vermes; Eyal Kalanthroff; Anthony Pinto; Chang-Gyu Hahn; Bin Xu; Page E Van Meter; Martha Katechis; Jennifer Scodes; Yuanjia Wang
Journal:  Behav Res Ther       Date:  2021-05-29

9.  Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.

Authors:  Gwenn S Smith; Hiroto Kuwabara; Neda F Gould; Najilla Nassery; Alena Savonenko; Jin Hui Joo; Kristin L Bigos; Michael Kraut; James Brasic; Daniel P Holt; Andrew W Hall; William B Mathews; Robert F Dannals; Ayon Nandi; Clifford I Workman
Journal:  Neuropharmacology       Date:  2021-01-12       Impact factor: 5.273

10.  Polythiophene-Chitosan Magnetic Nanocomposite as a Highly Efficient Medium for Isolation of Fluoxetine from Aqueous and Biological Samples.

Authors:  Shokooh Ehteshami; Alireza Feizbakhsh; Amir Hossein Mohsen Sarrafi
Journal:  J Anal Methods Chem       Date:  2016-09-08       Impact factor: 2.193

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.